William Hersh, M.D., writes, “While I am aghast at those who want to re-open the economy or the schools too fast, or not wear masks, I crave the return to normal life as much as they do.”
The American Psychiatric Association’s new treatment guidelines for schizophrenia are covered. George Keepers, M.D., who chaired the panel that authored the guidelines, says, “Patients are often treated with an effective medication and then forced, by circumstances or their insurance company, to switch to another that may not be effective for them, resulting in unnecessary relapses of the illness.”
In a story about the pitfalls of a public health strategy that depends upon testing, Mark Slifka, Ph.D, says a hypothetical patient “could be on the downward slope, where he’s already cleared it, and would continue to be less likely to transmit. Or it could be the opposite, where he has a viral load that’s low and then goes up.”
An editorial calls for police reform, citing head injury during arrest of OHSU intensive care nurse Tyler Cox, R.N., who was volunteering as a medic during downtown protest.
In a story about overactive bladders, Thomas Gregory, M.D., says, “Either the nerves that provide information about sensation receive, or think they receive, information about being full or irritated, or the nerves that send signals to the muscle of the bladder are too active, and the muscle contracts.”
Nike co-founder Phil Knight and his wife, Penny will receive the 2020 Association of American Cancer Institutes “Champion for Cures Award.” Brian Druker, M.D., says: “Their remarkable vision motivated more than 10,000 people in Oregon—and around the world—to recognize an extraordinary opportunity to support our mission to end cancer as we know it. The Knights’ incredible generosity leaves an indelible legacy in the world of cancer research, and will no doubt impact generations to come.”
In a story on the impact of COVID-19 on prostate cancer care, Tom Beer, M.D., says: “Medical treatment for advanced cancer was universally treated as essential. We did not delay any hormonal therapy or chemotherapy or immunotherapy. And we did not delay participation and treatment in clinical trials. We were able to continue most of our clinical research.”